The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study
- PMID: 18042302
- PMCID: PMC2148046
- DOI: 10.1186/1472-6963-7-193
The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study
Abstract
Background: Health care policies, including drug-funding policies, influence physician practice. Funding policies are especially important in the area of cancer care since cancer is a leading cause of death that is responsible for a significant level of health care expenditures. Recognizing the rising cost of cancer therapies, Cancer Care Ontario (CCO) established a funding process to provide access to new, effective agents through a "New Drug Funding Program" (NDFP). The purpose of this study is to describe oncologists' perceptions of the impact of NDFP priority setting decisions on their practice.
Methods: This is a qualitative study involving semi-structured, in-depth interviews with 46 medical oncologists in Ontario. Oncologists were asked to describe the impact of CCO's NDFP drug funding decisions on their practice. Analysis of interview transcripts commenced with data collection.
Results: Our key finding is that many of the medical oncologists who participated in this study did not accept limits when policy decisions limit access to cancer drugs they feel would benefit their patients. Moreover, overcoming those limits had a significant impact on oncologists' practice in terms of how they spend their time and energy and their relationship with patients.
Conclusion: When priority setting decisions limit access to cancer medications, many oncologists' efforts to overcome those limits have a significant impact on their practice. Policy makers need to seriously consider the implications of their decisions on physicians, who may go to considerable effort to circumvent their policies in the name of patient advocacy.
Similar articles
-
Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.J Clin Oncol. 2010 Sep 20;28(27):4149-53. doi: 10.1200/JCO.2010.29.1625. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697077
-
Rationing cancer treatment: a qualitative study of perceptions of legitimate limit-setting.BMC Health Serv Res. 2018 May 9;18(1):342. doi: 10.1186/s12913-018-3137-3. BMC Health Serv Res. 2018. PMID: 29743065 Free PMC article.
-
Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario.Curr Oncol. 2021 Feb 26;28(2):1056-1066. doi: 10.3390/curroncol28020103. Curr Oncol. 2021. PMID: 33652898 Free PMC article.
-
Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.J Clin Oncol. 2007 Jan 10;25(2):233-7. doi: 10.1200/JCO.2006.09.2437. J Clin Oncol. 2007. PMID: 17210946 Review.
-
Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.ESMO Open. 2019 Nov 13;4(6):e000550. doi: 10.1136/esmoopen-2019-000550. eCollection 2019. ESMO Open. 2019. PMID: 31798977 Free PMC article. Review.
Cited by
-
Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.Int J Health Policy Manag. 2015 Oct 20;5(2):99-105. doi: 10.15171/ijhpm.2015.186. Int J Health Policy Manag. 2015. PMID: 26927395 Free PMC article.
-
Variation and consternation: access to unfunded cancer drugs in Canada.J Oncol Pract. 2012 Jan;8(1):35-9. doi: 10.1200/JOP.2011.000278. J Oncol Pract. 2012. PMID: 22548009 Free PMC article.
-
Moral Distress and Resilience Associated with Cancer Care Priority Setting in a Resource-Limited Context.Oncologist. 2021 Jul;26(7):e1189-e1196. doi: 10.1002/onco.13818. Epub 2021 May 28. Oncologist. 2021. PMID: 33969927 Free PMC article.
-
Access to cancer drugs in Canada: looking beyond coverage decisions.Healthc Policy. 2011 Feb;6(3):27-36. doi: 10.12927/hcpol.2011.22177. Healthc Policy. 2011. PMID: 22294989 Free PMC article.
-
Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges.J Oncol Pract. 2013 Jul;9(4):188-93. doi: 10.1200/JOP.2012.000680. Epub 2013 Jan 2. J Oncol Pract. 2013. PMID: 23942919 Free PMC article.
References
-
- Eddy DM. Clinical policies and the quality of clinical practice. N Engl J Med. 1982;307:343–7. - PubMed
-
- Canadian Cancer Society/National Cancer Institute of Canada Canadian Cancer Statistics 2006 Toronto, Canada. 2006.
-
- Moore R, Mao Y, Zhang J, Clarke K. Economic Burden of Illness in Canada. Ottawa: Health Canada; 1997. - PubMed
-
- Pater JL, Browman GP, Brouwers MC, Nefsky MF, Evans WK, Cowan DH. Funding new cancer drugs in Ontario: closing the loop in the practice guidelines development cycle. J Clin Oncol. 2001;19:3392–6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical